Publications by authors named "Thomas Ischinger"

Claim this Profile
F
First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
Maik J Grundeken, Joanna J Wykrzykowska, Yuki Ishibashi, Scot Garg, Ton de Vries, Thomas Ischinger

Catheter Cardiovasc Interv· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EMPIRE Study-Review and Comment.
Thomas A Ischinger

Indian Heart J· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis.
Albert Markus Kasel, Salvatore Cassese, Thomas Ischinger, Alexander Leber, Diethmar Antoni

Am J Cardiovasc Dis· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Patrick W Serruys, Vasim Farooq, Bindu Kalesan, Ton de Vries, Pawel Buszman, Thomas Ischinger

JACC Cardiovasc Interv· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aortic valve calcium score as a predictor for outcome after TAVI using the CoreValve revalving system.
Alexander W Leber, Markus Kasel, Thomas Ischinger, Ulrich H Ebersberger, Diethmar Antoni

Int J Cardiol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Giulio G Stefanini, Bindu Kalesan, Patrick W Serruys, Dik Heg, Pawel Buszman, Thomas Ischinger

Lancet· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Joanna Wykrzykowska, Patrick Serruys, Pawel Buszman, Axel Linke, Thomas Ischinger

EuroIntervention· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "all-comers" LEADERS trial.
Joanna J Wykrzykowska, Scot Garg, Yoshinobu Onuma, Ton de Vries, Marie-Angele Morel, Thomas Ischinger

EuroIntervention· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Volker Klauss, Patrick W Serruys, Thomas Pilgrim, Pawel Buszman, Axel Linke, Thomas Ischinger

JACC Cardiovasc Interv· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
Giulio G Stefanini, Patrick W Serruys, Sigmund Silber, Ahmed A Khattab, Robert J van Geuns, Thomas Ischinger

J Am Coll Cardiol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
Scot Garg, Patrick W Serruys, Sigmund Silber, Joanna Wykrzykowska, Robert Jan van Geuns, Thomas Ischinger

JACC Cardiovasc Interv· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.
Scot Garg, Joanna Wykrzykowska, Patrick W Serruys, Ton de Vries, Pawel Buszman, Thomas Ischinger

EuroIntervention· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial.
Joanna J Wykrzykowska, Scot Garg, Yoshinobu Onuma, Ton de Vries, Dick Goedhart, Thomas Ischinger

Circ Cardiovasc Interv· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid artery interventions for restenosis after prior stenting: is it different from interventions of de novo lesions? Results from the carotid artery stent (CAS)--registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
Ralf Zahn, Thomas Ischinger, Uwe Zeymer, Johannes Brachmann, Jens Jung

Clin Res Cardiol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
Patrick W Serruys, Sigmund Silber, Scot Garg, Robert Jan van Geuns, Gert Richardt, Thomas Ischinger

N Engl J Med· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
Joanna J Wykrzykowska, Scot Garg, Chrysafios Girasis, Ton de Vries, Marie-Angele Morel, Thomas Ischinger

J Am Coll Cardiol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer.
Scot Garg, Giovanna Sarno, Patrick W Serruys, Ton de Vries, Pawel Buszman, Thomas Ischinger

EuroIntervention· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).
Giovanna Sarno, Scot Garg, Yoshinobu Onuma, Pawel Buszman, Axel Linke, Thomas Ischinger

Am J Cardiol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of carotid artery stenting for significant carotid stenosis in patients with contralateral occlusion (from the German ALKK-CAS Registry experience).
Rajendra H Mehta, Ralf Zahn, Matthias Hochadel, Harald Mudra, Thomas Ischinger

Am J Cardiol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.
Joanna J Wykrzykowska, Patrick W Serruys, Yoshinobu Onuma, Ton de Vries, Gerrit-Anne van Es, Thomas Ischinger

JACC Cardiovasc Interv· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.
Joanna J Wykrzykowska, Lorenz Räber, Ton de Vries, Marco Bressers, Pawel Buszman, Thomas Ischinger

EuroIntervention· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid artery stenting: do procedural complications relate to the side intervened upon?: results from the Carotid Artery Stent (CAS)-Registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
Ralf Zahn, Thomas Ischinger, Matthias Hochadel, Bernd Mark, Uwe Zeymer

Catheter Cardiovasc Interv· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
Stephan Windecker, Patrick W Serruys, Simon Wandel, Pawel Buszman, Stanislaw Trznadel, Thomas Ischinger

Lancet· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of in-hospital outcomes of patients with versus without previous carotid endarterectomy undergoing carotid stenting (from the German ALKK CAS Registry).
Rajendra H Mehta, Ralf Zahn, Matthias Hochadel, Thomas Ischinger, Jens Jung

Am J Cardiol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid artery stenting in octogenarians: results from the ALKK Carotid Artery Stent (CAS) Registry.
Ralf Zahn, Thomas Ischinger, Matthias Hochadel, Uwe Zeymer, Wolfgang Schmalz

Eur Heart J· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis